Vanda Pharmaceuticals | VNDA - Loan Capital


Vanda Pharmaceuticals reported $3.15M in Loan Capital for its fiscal quarter ending in December of 2024.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Akebia Therapeutics USD 48.25M 609K Dec/2025
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
Arrowhead Research USD 538.1M 323.22M Dec/2025
AstraZeneca USD 25.96B 177M Mar/2026
Bristol-Myers Squibb USD 42.15B 698M Mar/2026
Eli Lilly USD 39.37B 1.5B Mar/2026
Enanta Pharmaceuticals USD 0 0 Dec/2024
Esperion Therapeutics USD 457.65M 9.5M Dec/2025
Halozyme Therapeutics USD 2.14B 1.34B Dec/2025
Heron Therapeutics USD 140.64M 975K Dec/2025
Insmed USD 540.96M 1.24M Dec/2025
J&J USD 37.53B 1.91B Mar/2026
Lexicon Pharmaceuticals USD 49.41M 7.1M Dec/2025
Ligand Pharmaceuticals USD 445.49M 445.44M Sep/2025
Merck USD 46.67B 77M Mar/2026
Minerva Neurosciences USD 0 86.58M Sep/2024
Moderna USD 603M 7M Mar/2026
Novartis USD 29.59B 5.35B Dec/2025
Pfizer USD 60.57B 1.08B Mar/2026
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Puma Biotechnology USD 10.87M 222K Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 13.84B 1.88B Mar/2026
Takeda JPY 4.27T 81.29B Dec/2025
Teva Pharmaceutical Industries USD 14.02B 971M Mar/2026
Ultragenyx Pharmaceutical USD 1.15B 383.26M Dec/2025
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024
Veracyte USD 0 0 Mar/2025